Jensen Klavs F. 4
4 · SQZ Biotechnologies Co · Filed Nov 3, 2020
Insider Transaction Report
Form 4
Jensen Klavs F.
Director
Transactions
- Conversion
Common Stock
[F1]2020-11-03+14,662→ 338,982 total - Conversion
Series Seed Convertible Preferred Stock
[F1]2020-11-03−7,017→ 0 total→ Common Stock (7,388 underlying) - Conversion
Series B Convertible Preferred Stock
[F1]2020-11-03−6,908→ 0 total→ Common Stock (7,274 underlying)
Footnotes (1)
- [F1]The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock automatically converted on a 1.053 for one basis into common stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Signature
/s/ Lawrence Knopf, Attorney-in-Fact for Klavs F. Jensen|2020-11-03